FDA Grants Fast Track Designation For DB102 in Patients with Newly-Diagnosed Glioblastoma (GBM)
SAN DIEGO, July 17, 2020 /PRNewswire/ -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DB102 (enzastaurin) being developed for the potential treatment of patients with newly-diagnosed glioblastoma. Fast Track designation may potentially expedite the review of a drug that is intended for the treatment of a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need for such a disease or condition.
Despite numerous attempts by many drug companies, GBM remains one of the deadliest cancers and the first line drug treatment still relies on temozolomide as the backbone. Many promising anticancer drugs, including anti-PD-1 drugs, failed to surpass temozolomide's efficacy. With Denovo's newly discoveried DGM1 biomarker, it was found that the addition of enzastaurin may improve outcomes in glioblastoma patients who possess the DGM1 biomarker and are exposed to a high dose of DB102, regardless of MGMT methylation status. Denovo plans to conduct a randomized, double-blind, placebo-controlled Phase 3 pivotal study of enzastaurin in combination with temozolomide, both during and following radiation therapy, in newly-diagnosed glioblastoma patients.
"This Fast Track designation in GBM is an important milestone in the development of DB102," said Xiao-Xiong Lu, Ph.D., Denovo's Chief Technical Officer. "We are pleased that FDA has recognized our innovative biomarker approach to conquer GBM. It potentially accelerates our development of DB102 in GBM, a difficult-to-treat indication with a significant unmet need and adds value to our DB102 franchise."
About Denovo Biopharma LLC
View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-for-db102-in-patients-with-newly-diagnosed-glioblastoma-gbm-301095274.html
SOURCE Denovo Biopharma LLC